Drug 'could herald precision medicine' in multiple myeloma
Results from an international trial of venetoclax may prove to be a watershed, a leading haematological oncologist says
A trial of the oral BCL-2 inhibitor venetoclax in a triple therapy regimen for multiple myeloma suggests certain patients might benefit from the new agent, despite an excess of fatal infections.
Plasma cells in a marrow film on a myeloma patient.
In the phase 3 international BELLINI trial, which included
